Yellow Fever Virus Vaccine: Stretching the Supply

In a trial in sub-Saharan Africa, safety and immunogenicity were similar for one-fifth compared with standard doses of yellow fever virus vaccines from various manufacturers.

Although the yellow fever virus vaccine (YFVV) has high, durable efficacy, recent viral outbreaks in Africa and South America have accelerated demands on an already fragile YFVV supply chain. Accordingly, outbreak control with fractional (one-fifth) YFVV doses was successfully employed in Brazil. To test the generalizability of this approach, investigators in sub-Saharan Africa performed a double-blind, randomized evaluation of the immunogenicity and safety of one-fifth dosing compared standard dosing of YFVV from four different manufacturers.

In all, 960 subjects were randomized to standard or fractional dosing of one of the four YFVVs. At 28 days postvaccination (the primary endpoint), seroconversion rates ranged from 98.2% to 100.0% (stan…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Yellow Fever Virus Vaccine: Stretching the Supply

Topics

Reviewing Author